{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=17", "query": { "intervention": "atezolizumab", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 512, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T02:09:08.848Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02605915", "title": "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-Positive Metastatic Breast Cancer", "HER2-Negative Metastatic Breast Cancer", "Locally Advanced or Early Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2015-12-31", "completion_date": "2019-11-13", "has_results": false, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605915" }, { "nct_id": "NCT03256344", "title": "Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Triple Negative Breast Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2018-03-19", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York • Stony Brook, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03256344" }, { "nct_id": "NCT05018273", "title": "Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, Adult" ], "interventions": [ { "name": "VB10.NEO", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nykode Therapeutics ASA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-12-21", "completion_date": "2024-10-09", "has_results": false, "last_update_posted_date": "2024-12-03", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 5, "location_summary": "San Francisco, California • New Haven, Connecticut • Louisville, Kentucky + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05018273" }, { "nct_id": "NCT05243862", "title": "Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "PolyPEPI1018", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Treos Bio Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-06-02", "completion_date": "2025-01-14", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243862" }, { "nct_id": "NCT03637764", "title": "Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "Isatuximab SAR650984", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2018-08-06", "completion_date": "2022-05-11", "has_results": true, "last_update_posted_date": "2023-07-10", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 3, "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03637764" }, { "nct_id": "NCT04665843", "title": "A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of Head and Neck" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2021-03-02", "completion_date": "2025-08-27", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Tallahassee, Florida + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665843" }, { "nct_id": "NCT05968326", "title": "A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma, Pancreatic Ductal" ], "interventions": [ { "name": "Autogene cevumeran", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2023-10-18", "completion_date": "2031-01-01", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 30, "location_summary": "Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05968326" }, { "nct_id": "NCT07226999", "title": "Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Small Cell Lung Cancer (SCLC)" ], "interventions": [ { "name": "PF-08634404", "type": "DRUG" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2025-12-09", "completion_date": "2034-03-11", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 54, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 41 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226999" }, { "nct_id": "NCT03267940", "title": "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cholangiocarcinoma Non-resectable", "Cholangiocarcinoma, Intrahepatic", "Cholangiocarcinoma, Extrahepatic", "Gallbladder Adenocarcinoma" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "CIS", "type": "DRUG" }, { "name": "GEM", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Halozyme Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2017-10-02", "completion_date": "2019-11-11", "has_results": true, "last_update_posted_date": "2020-02-07", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03267940" }, { "nct_id": "NCT04923776", "title": "Liver Directed RT + Chemo-immunotherapy for ES-SCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small-cell Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Brian Henick, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-09-20", "completion_date": "2023-12-23", "has_results": true, "last_update_posted_date": "2024-12-30", "last_synced_at": "2026-10-14T02:09:08.848Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04923776" } ] }